Literature DB >> 1548776

Probing protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1 by in vivo footprinting.

F Demarchi1, P D'Agaro, A Falaschi, M Giacca.   

Abstract

We have analyzed protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1 in a productively infected T-cell line by in vivo dimethyl sulfate footprinting. Major footprints are evident at the basal promoter and enhancer elements. In particular, proteins appear to occupy the TATA box, the Sp1 sites, and the two repeats of the enhancer region. In the negative regulatory element, protections are detected over the USF/MLTF and NFAT-1 sites. Furthermore, two previously unrecognized sites, from nucleotides -260 to -275 and from nucleotides -205 to -216, respectively, appear to be involved in protein-DNA interactions. These two sites are purine rich and share a common sequence motif.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548776      PMCID: PMC289049     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Characterization of cellular proteins recognizing the HIV enhancer using a microscale DNA-affinity precipitation assay.

Authors:  B R Franza; S F Josephs; M Z Gilman; W Ryan; B Clarkson
Journal:  Nature       Date:  1987 Nov 26-Dec 2       Impact factor: 49.962

2.  In vivo footprinting of a muscle specific enhancer by ligation mediated PCR.

Authors:  P R Mueller; B Wold
Journal:  Science       Date:  1989-11-10       Impact factor: 47.728

3.  Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1.

Authors:  Y C Lu; N Touzjian; M Stenzel; T Dorfman; J G Sodroski; W A Haseltine
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

Review 4.  Regulatory pathways governing HIV-1 replication.

Authors:  B R Cullen; W C Greene
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

5.  NF-kappa B protein purification from bovine spleen: nucleotide stimulation and binding site specificity.

Authors:  M J Lenardo; A Kuang; A Gifford; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity.

Authors:  J Leonard; C Parrott; A J Buckler-White; W Turner; E K Ross; M A Martin; A B Rabson
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  The same 50-kDa cellular protein binds to the negative regulatory elements of the interleukin 2 receptor alpha-chain gene and the human immunodeficiency virus type 1 long terminal repeat.

Authors:  M R Smith; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer.

Authors:  L Clark; J R Matthews; R T Hay
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

9.  Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters.

Authors:  K A Jones; P A Luciw; N Duchange
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

10.  Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation.

Authors:  J A Garcia; D Harrich; E Soultanakis; F Wu; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

View more
  14 in total

Review 1.  A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter.

Authors:  L A Pereira; K Bentley; A Peeters; M J Churchill; N J Deacon
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

2.  Interactions of HTF4 with E-box motifs in the long terminal repeat of human immunodeficiency virus type 1.

Authors:  Y Zhang; K Doyle; M Bina
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

3.  Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1.

Authors:  F Demarchi; F d'Adda di Fagagna; A Falaschi; M Giacca
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Molecular and functional interactions of transcription factor USF with the long terminal repeat of human immunodeficiency virus type 1.

Authors:  F d'Adda di Fagagna; G Marzio; M I Gutierrez; L Y Kang; A Falaschi; M Giacca
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  In vivo footprinting analysis of constitutive and inducible protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1.

Authors:  F Demarchi; P D'Agaro; A Falaschi; M Giacca
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 6.  The quest for a human ori.

Authors:  A Falaschi; M Giacca
Journal:  Genetica       Date:  1994       Impact factor: 1.082

7.  A modified protocol for in vivo footprinting by ligation-mediated polymerase chain reaction.

Authors:  D Dimitrova; M Giacca; A Falaschi
Journal:  Nucleic Acids Res       Date:  1994-02-11       Impact factor: 16.971

8.  Involvement of transcription factor YB-1 in human T-cell lymphotropic virus type I basal gene expression.

Authors:  F Kashanchi; J F Duvall; J Dittmer; A Mireskandari; R L Reid; S D Gitlin; J N Brady
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

9.  Adeno-associated virus type 2 rep gene-mediated inhibition of basal gene expression of human immunodeficiency virus type 1 involves its negative regulatory functions.

Authors:  I Oelze; K Rittner; G Sczakiel
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Characterization of nuclear proteins that bind to the regulatory TGATTGGC motif in the human immunodeficiency virus type 1 long terminal repeat.

Authors:  C Schwartz; F Canonne-Hergaux; D Aunis; E Schaeffer
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.